Press Release Apr 28 2026
Filed with NSE · · 39 pages · English
Summary by 6ix AI
The report highlights a transitional year impacted by external disruptions, but the company expects a return to growth in the upcoming fiscal year. Key developments include the completion of the Kenalog acquisition and a focus on cost optimization to mitigate revenue impacts. The company also reported no increase in net debt compared to the previous fiscal year, indicating stable financial management.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Piramal Pharma
- Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
- Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
- Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Later from Piramal Pharma
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
- Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
- Piramal Pharma Limited Announces Results for Q1 FY27
Follow Piramal Pharma into a list and get an email when it puts out news.
Follow Piramal Pharma